About Ernexa Therapeutics Inc. - Common Stock (ERNA)
Eterna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for the treatment of severe diseases through advanced genetic and cell-based solutions. The company leverages its proprietary technology platform to create therapies that harness the power of RNA and protein engineering, aiming to address unmet medical needs in various therapeutic areas. By integrating cutting-edge research and development processes, Eterna Therapeutics strives to transform the landscape of treatment options available for patients, particularly in the fields of oncology and rare genetic disorders. Read More
The search for stocks under $1, penny stocks with momentum , and micro-cap growth opportunities continues to trend across retail trading platforms and AI-driven discovery engines. As market volatility increases and investors look for asymmetric upside potential, several sub-$1 equities are drawing heightened attention due to sector positioning, news catalysts, and unusual trading activity.
Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, announced continued momentum for its flagship brand FOCUSfactor® following several key milestones and retail expansions across North America, UK, UAE, Turkey and Latin America.
The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
